Horizon Discovery has signed a research service collaboration deal with Boehringer Ingelheim to support Boehringer’s oncology programs by using Horizon’s Discovery toolbox for research projects and profiling compounds at the hit-to-lead, lead optimization, and preclinical stages to elucidate their anticancer properties and help guide drug discovery programs.
Under terms of the collaboration, Horizon will evaluate compounds across a broad panel of X-Man isogenic models and selected 2D/3D phenotypic assays and provide an FTE and access to Horizon’s custom cell line generation services to support the programs.
Horizon will also apply its Genesis genome editing technology to develop human isogenic disease model cell lines, according to Boehringer’s specifications. Using Genesis, Horizon can alter any endogenous gene sequence of human or mammalian cell lines quickly, reliably, and without unwanted and confounding genotypes or phenotypes. The resulting high-quality cell lines accurately model the disease-causing mutations found in patients.
Horizon Discovery, 44(0)12 2365 5580
Boehringer Ingelheim, 203-798-9988